Diabetes Management in Patients with Heart Failure
Diabetes and heart failure (HF) are common diseases, each affecting large segments of the world population. Moreover, prevalence rates for both are expected to rise dramatically over coming decades. The high prevalence rates of both diseases and well-recognized association of diabetes as a risk fact...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Diabetes Association
2021-03-01
|
Series: | Diabetes & Metabolism Journal |
Subjects: | |
Online Access: | http://www.e-dmj.org/upload/pdf/dmj-2020-0296.pdf |
id |
doaj-15d1dd77bdf54e66b1dcad34455fac60 |
---|---|
record_format |
Article |
spelling |
doaj-15d1dd77bdf54e66b1dcad34455fac602021-04-02T01:07:41ZengKorean Diabetes AssociationDiabetes & Metabolism Journal2233-60792233-60872021-03-0145215817210.4093/dmj.2020.02962540Diabetes Management in Patients with Heart FailureJia Shen0Barry H. Greenberg1 Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, CA, USADiabetes and heart failure (HF) are common diseases, each affecting large segments of the world population. Moreover, prevalence rates for both are expected to rise dramatically over coming decades. The high prevalence rates of both diseases and well-recognized association of diabetes as a risk factor for HF make it inevitable that both diseases co-exist in a large number of patients, complicating their management and increasing the risk of a poor outcome. Management of diabetes has been shown to impact clinical events in patients with HF and there is emerging evidence that agents used to treat diabetes can reduce HF events, even in non-diabetic patients. In this review we summarize the clinical course and treatment of patients with type 2 diabetes mellitus (T2DM) and HF and review the efficacy and safety of pharmacological agents in patients with T2DM at risk for HF and those with established disease.http://www.e-dmj.org/upload/pdf/dmj-2020-0296.pdfdiabetes mellitusheart failurerisk factorssodium glucose cotransporter 2 inhibitor |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jia Shen Barry H. Greenberg |
spellingShingle |
Jia Shen Barry H. Greenberg Diabetes Management in Patients with Heart Failure Diabetes & Metabolism Journal diabetes mellitus heart failure risk factors sodium glucose cotransporter 2 inhibitor |
author_facet |
Jia Shen Barry H. Greenberg |
author_sort |
Jia Shen |
title |
Diabetes Management in Patients with Heart Failure |
title_short |
Diabetes Management in Patients with Heart Failure |
title_full |
Diabetes Management in Patients with Heart Failure |
title_fullStr |
Diabetes Management in Patients with Heart Failure |
title_full_unstemmed |
Diabetes Management in Patients with Heart Failure |
title_sort |
diabetes management in patients with heart failure |
publisher |
Korean Diabetes Association |
series |
Diabetes & Metabolism Journal |
issn |
2233-6079 2233-6087 |
publishDate |
2021-03-01 |
description |
Diabetes and heart failure (HF) are common diseases, each affecting large segments of the world population. Moreover, prevalence rates for both are expected to rise dramatically over coming decades. The high prevalence rates of both diseases and well-recognized association of diabetes as a risk factor for HF make it inevitable that both diseases co-exist in a large number of patients, complicating their management and increasing the risk of a poor outcome. Management of diabetes has been shown to impact clinical events in patients with HF and there is emerging evidence that agents used to treat diabetes can reduce HF events, even in non-diabetic patients. In this review we summarize the clinical course and treatment of patients with type 2 diabetes mellitus (T2DM) and HF and review the efficacy and safety of pharmacological agents in patients with T2DM at risk for HF and those with established disease. |
topic |
diabetes mellitus heart failure risk factors sodium glucose cotransporter 2 inhibitor |
url |
http://www.e-dmj.org/upload/pdf/dmj-2020-0296.pdf |
work_keys_str_mv |
AT jiashen diabetesmanagementinpatientswithheartfailure AT barryhgreenberg diabetesmanagementinpatientswithheartfailure |
_version_ |
1724175274727178240 |